Andrew Berens

Kinnate Biopharma Inc (NASDAQ: KNTE), which focuses on developing small-molecule kinase inhibitors for difficult-to-treat, genomically-defined cancers, recently raised $276 million in gross proceeds in an initial public offering priced at $20 per share. The Kinnate Biopharma Analyst:...

AstraZeneca plc's (NYSE: AZN) prospects at being the first mover in the competition to develop a coronavirus vaccine have dimmed, according to an analyst at SVB Leerink. The AstraZeneca Analyst: Andrew Berens has an Outperform rating on AstraZeneca with a $65 price target. The...

Clinical-stage biopharma company Epizyme Inc (NASDAQ: EPZM)'s tazemetostat has shown effectiveness in treating blood cancers and solid tumors with minimal toxicities in early- and mid-stage trials, according to Morgan Stanley.  Tazemetostat is an EZH2 inhibitor that moderates gene...

Morgan Stanley said in a note Tuesday it would be buyers of Clovis Oncology Inc (NASDAQ: CLVS) and TESARO Inc (NASDAQ: TSRO) ahead of the Lynparza label decision. AstraZeneca plc (ADR) (NYSE: AZN)'s Lynparza is a poly polymerase, or PARP, inhibitor indicated for use as a monotherapy in patients...

Morgan Stanley's Andrew Berens downgraded shares of Cempra Inc (NASDAQ: CEMP) to Underweight from Overweight with a price target slashed to $5 from $35 following the U.S. Food and Drug Administration's vote. The FDA's Antimicrobial Disease Advisory Committee voted in favor of Cempra...

Shares of Cempra Inc (NASDAQ: CEMP) plunged 60 percent to a new 52-week low of $7.35 after FDA briefing documents questioned whether solithromycin has some of the same safety risks as Ketek and potential for liver toxicity. The FDA issue came on the heels of company announcing the receipt of a $10...

Morgan Stanley's Andrew Berens maintained Intercept Pharmaceutical Inc (NASDAQ: ICPT)'s Underweight rating with a price target of $80. The initiation came after the FCC granted accelerated approval to Intercept's Ocaliva product for treating patients with primary biliary cirrhosis (...

Intercept Pharmaceuticals Inc (NASDAQ: ICPT) shares are trading lower by $10.35 at $153.45 in Friday's session. It has been a volatile session for the issue and even more volatile if one takes into the price action if the after-hours and pre-market sessions. A little bit of history on the issue...

Shares of Relypsa Inc (NASDAQ: RLYP) were trading higher by more than 8 percent early Friday morning. The stock plunged more than 13 percent on Thursday following a bear research report by Elliot Favus of Favus Institutional Research. Adam Feuerstein, a senior columnist with The Street and known...

The following represents a hand-picked selection of notable research curated by an analyst known in some circles as "The Sith Overlord Of The Street." Morgan Stanley: Initiating Intercept Pharmaceutical At Underperform Andrew Berens of Morgan Stanley initiated coverage of Intercept Pharmaceuticals...